The Risk of Cancer in Patients With Psoriasis: A Population-Based Cohort Study in the Health Improvement Network | Cancer Screening, Prevention, Control | JAMA Dermatology | JAMA Network
[Skip to Navigation]
Access to paid content on this site is currently suspended due to excessive activity being detected from your IP address 34.239.150.57. Please contact the publisher to request reinstatement.
1.
Pouplard  C, Brenaut  E, Horreau  C,  et al.  Risk of cancer in psoriasis: a systematic review and meta-analysis of epidemiological studies.  J Eur Acad Dermatol Venereol. 2013;27(suppl 3):36-46.PubMedGoogle ScholarCrossref
2.
Abuabara  K, Azfar  RS, Shin  DB, Neimann  AL, Troxel  AB, Gelfand  JM.  Cause-specific mortality in patients with severe psoriasis: a population-based cohort study in the U.K.  Br J Dermatol. 2010;163(3):586-592.PubMedGoogle ScholarCrossref
3.
Gelfand  JM, Berlin  J, Van Voorhees  A, Margolis  DJ.  Lymphoma rates are low but increased in patients with psoriasis: results from a population-based cohort study in the United Kingdom.  Arch Dermatol. 2003;139(11):1425-1429.PubMedGoogle Scholar
4.
Gelfand  JM, Shin  DB, Neimann  AL, Wang  X, Margolis  DJ, Troxel  AB.  The risk of lymphoma in patients with psoriasis.  J Invest Dermatol. 2006;126(10):2194-2201.PubMedGoogle ScholarCrossref
5.
Boffetta  P, Gridley  G, Lindelöf  B.  Cancer risk in a population-based cohort of patients hospitalized for psoriasis in Sweden.  J Invest Dermatol. 2001;117(6):1531-1537.PubMedGoogle ScholarCrossref
6.
Chen  YJ, Wu  CY, Chen  TJ,  et al.  The risk of cancer in patients with psoriasis: a population-based cohort study in Taiwan.  J Am Acad Dermatol. 2011;65(1):84-91.PubMedGoogle ScholarCrossref
7.
Margolis  D, Bilker  W, Hennessy  S, Vittorio  C, Santanna  J, Strom  BL.  The risk of malignancy associated with psoriasis.  Arch Dermatol. 2001;137(6):778-783.PubMedGoogle Scholar
8.
Brauchli  YB, Jick  SS, Miret  M, Meier  CR.  Psoriasis and risk of incident cancer: an inception cohort study with a nested case-control analysis.  J Invest Dermatol. 2009;129(11):2604-2612.PubMedGoogle ScholarCrossref
9.
Stern  RS, Väkevä  LH; PUVA Follow-up Study.  Noncutaneous malignant tumors in the PUVA follow-up study: 1975-1996.  J Invest Dermatol. 1997;108(6):897-900.PubMedGoogle ScholarCrossref
10.
Dregan  A, Moller  H, Murray-Thomas  T, Gulliford  MC.  Validity of cancer diagnosis in a primary care database compared with linked cancer registrations in England: population-based cohort study.  Cancer Epidemiol. 2012;36(5):425-429.PubMedGoogle ScholarCrossref
11.
Haynes  K, Forde  KA, Schinnar  R, Wong  P, Strom  BL, Lewis  JD.  Cancer incidence in The Health Improvement Network.  Pharmacoepidemiol Drug Saf. 2009;18(8):730-736.PubMedGoogle ScholarCrossref
12.
Meal  A, Leonardi-Bee  J, Smith  C, Hubbard  R, Bath-Hextall  F.  Validation of THIN data for non-melanoma skin cancer.  Qual Prim Care. 2008;16(1):49-52.PubMedGoogle Scholar
13.
Seminara  NM, Abuabara  K, Shin  DB,  et al.  Validity of The Health Improvement Network (THIN) for the study of psoriasis.  Br J Dermatol. 2011;164(3):602-609.PubMedGoogle Scholar
14.
Blak  BT, Thompson  M, Dattani  H, Bourke  A.  Generalisability of The Health Improvement Network (THIN) database: demographics, chronic disease prevalence and mortality rates.  Inform Prim Care. 2011;19(4):251-255.PubMedGoogle Scholar
15.
Taggar  JS, Coleman  T, Lewis  S, Szatkowski  L.  The impact of the Quality and Outcomes Framework (QOF) on the recording of smoking targets in primary care medical records: cross-sectional analyses from The Health Improvement Network (THIN) database.  BMC Public Health. 2012;12:329.PubMedGoogle ScholarCrossref
16.
Chisholm  J.  The Read clinical classification.  BMJ. 1990;300(6732):1092.PubMedGoogle ScholarCrossref
17.
Mehta  NN, Azfar  RS, Shin  DB, Neimann  AL, Troxel  AB, Gelfand  JM.  Patients with severe psoriasis are at increased risk of cardiovascular mortality: cohort study using the General Practice Research Database.  Eur Heart J. 2010;31(8):1000-1006.PubMedGoogle ScholarCrossref
18.
Bursac  Z, Gauss  CH, Williams  DK, Hosmer  DW.  Purposeful selection of variables in logistic regression.  Source Code Biol Med. 2008;3:17.PubMedGoogle ScholarCrossref
19.
Stern  RS; PUVA Follow-up Study.  The risk of melanoma in association with long-term exposure to PUVA.  J Am Acad Dermatol. 2001;44(5):755-761.PubMedGoogle ScholarCrossref
20.
Archier  E, Devaux  S, Castela  E,  et al.  Carcinogenic risks of psoralen UV-A therapy and narrowband UV-B therapy in chronic plaque psoriasis: a systematic literature review.  J Eur Acad Dermatol Venereol. 2012;26(suppl 3):22-31.PubMedGoogle ScholarCrossref
21.
Ekström  K, Hjalgrim  H, Brandt  L,  et al.  Risk of malignant lymphomas in patients with rheumatoid arthritis and in their first-degree relatives.  Arthritis Rheum. 2003;48(4):963-970.PubMedGoogle ScholarCrossref
22.
Ekström Smedby  K, Vajdic  CM, Falster  M,  et al.  Autoimmune disorders and risk of non-Hodgkin lymphoma subtypes: a pooled analysis within the InterLymph Consortium.  Blood. 2008;111(8):4029-4038.PubMedGoogle ScholarCrossref
23.
Frentz  G, Olsen  JH.  Malignant tumours and psoriasis: a follow-up study.  Br J Dermatol. 1999;140(2):237-242.PubMedGoogle ScholarCrossref
24.
Hannuksela-Svahn  A, Pukkala  E, Läärä  E, Poikolainen  K, Karvonen  J.  Psoriasis, its treatment, and cancer in a cohort of Finnish patients.  J Invest Dermatol. 2000;114(3):587-590.PubMedGoogle ScholarCrossref
25.
Ji  J, Shu  X, Sundquist  K, Sundquist  J, Hemminki  K.  Cancer risk in hospitalised psoriasis patients: a follow-up study in Sweden.  Br J Cancer. 2009;100(9):1499-1502.PubMedGoogle ScholarCrossref
26.
Prizment  AE, Alonso  A, Folsom  AR,  et al.  Association between psoriasis and incident cancer: the Iowa’s Women’s Health Study.  Cancer Causes Control. 2011;22(7):1003-1010.PubMedGoogle ScholarCrossref
27.
Paradisi  A, Tabolli  S, Didona  B, Sobrino  L, Russo  N, Abeni  D.  Reduced frequency of melanoma in 72,739 patients with psoriasis: a retrospective study.  Eur J Dermatol. 2015;25(2):133-137.PubMedGoogle Scholar
28.
Komura  T, Sakai  Y, Harada  K,  et al.  Inflammatory features of pancreatic cancer highlighted by monocytes/macrophages and CD4+ T cells with clinical impact.  Cancer Sci. 2015;106(6):672-686.PubMedGoogle ScholarCrossref
29.
McAleer  MA, Mason  DL, Cunningham  S,  et al.  Alcohol misuse in patients with psoriasis: identification and relationship to disease severity and psychological distress.  Br J Dermatol. 2011;164(6):1256-1261.PubMedGoogle ScholarCrossref
30.
Kirby  B, Richards  HL, Mason  DL, Fortune  DG, Main  CJ, Griffiths  CE.  Alcohol consumption and psychological distress in patients with psoriasis.  Br J Dermatol. 2008;158(1):138-140.PubMedGoogle Scholar
31.
Fantò  M, Peragallo  MS, Pietrosanti  M,  et al.  Risk of malignancy in patients with rheumatoid arthritis, psoriatic arthritis and ankylosing spondylitis under immunosuppressive therapy: a single-center experience [published online June 23, 2015].  Intern Emerg Med. doi:10.1007/s11739-015-1270-0.PubMedGoogle Scholar
32.
England  BR, Sayles  H, Michaud  K,  et al.  Cause-specific mortality in US veteran men with rheumatoid arthritis [published online June 19, 2015.  Arthritis Care Res (Hoboken). doi:10.1002/acr.22642.PubMedGoogle Scholar
33.
Ogdie  A, Haynes  K, Troxel  AB,  et al.  Risk of mortality in patients with psoriatic arthritis, rheumatoid arthritis and psoriasis: a longitudinal cohort study.  Ann Rheum Dis. 2014;73(1):149-153.PubMedGoogle ScholarCrossref
34.
Hearn  RM, Kerr  AC, Rahim  KF, Ferguson  J, Dawe  RS.  Incidence of skin cancers in 3867 patients treated with narrow-band ultraviolet B phototherapy.  Br J Dermatol. 2008;159(4):931-935.PubMedGoogle ScholarCrossref
35.
Armstrong  BK, Kricker  A.  The epidemiology of UV induced skin cancer.  J Photochem Photobiol B. 2001;63(1-3):8-18.PubMedGoogle ScholarCrossref
Original Investigation
March 2016

The Risk of Cancer in Patients With Psoriasis: A Population-Based Cohort Study in the Health Improvement Network

Author Affiliations
  • 1Departments of Dermatology, University of Pennsylvania Perelman School of Medicine, Philadelphia
  • 2Epidemiology and Biostatistics, Center for Clinical Epidemiology and Biostatistics, University of Pennsylvania Perelman School of Medicine, Philadelphia
  • 3Department of Rheumatology, University of Pennsylvania Perelman School of Medicine, Philadelphia
JAMA Dermatol. 2016;152(3):282-290. doi:10.1001/jamadermatol.2015.4847
Abstract

Importance  The risk of cancer in patients with psoriasis remains a cause of special concern due to the chronic inflammatory nature of the disease, the use of immune-suppressive treatments and UV therapies, and the increased prevalence of comorbid, well-established risk factors for cancer, such as smoking and obesity, all of which may increase the risk of carcinogenesis.

Objective  To compare the overall risk of cancer, and specific cancers of interest, in patients with psoriasis compared with patients without psoriasis.

Design, Setting, and Participants  Population-based cohort study of patients ages 18 to 89 years with no medical history of human immunodeficiency virus, cancer, organ transplants, or hereditary disease (albinism and xeroderma pigmentosum), prior to the start date, conducted using The Health Improvement Network, a primary care medical records database in the United Kingdom. The data analyzed had been collected prospectively from 2002 through January 2014. The analysis was completed in August 2015.

Exposures of Interest  Patients with at least 1 diagnostic code for psoriasis were classified as having moderate-to-severe disease if they had been prescribed psoralen, methotrexate, cyclosporine, acitretin, adalimumab, etanercept, infliximab, or ustekinumab or phototherapy for psoriasis. Patients were classified as having mild disease if they never received treatment with any of these agents.

Main Outcomes and Measures  Incident cancer diagnosis.

Results  A total of 937 716 control group patients without psoriasis, matched on date and practice visit, and 198 366 patients with psoriasis (186 076 with mild psoriasis and 12 290 with moderate-to-severe disease) were included in the analysis. The adjusted hazard ratios (aHRs) with 95% CIs for any incident cancer excluding nonmelanoma skin cancer (NMSC) were 1.06 (95% CI, 1.02-1.09), 1.06 (95% CI, 1.02-1.09), and 1.08 (95% CI, 0.96-1.22) in the overall, mild, and severe psoriasis group. The aHRs for incident lymphoma were 1.34 (95% CI, 1.18-1.51), 1.31 (95% CI, 1.15-1.49), and 1.89 (95% CI, 1.25-2.86); for NMSC, 1.12 (95% CI, 1.07-1.16), 1.09 (95% CI, 1.05-1.13), and 1.61 (95% CI, 1.42-1.84); and for lung cancer, 1.15 (95% CI, 1.03-1.27), 1.12 (95% CI, 1.01-1.25), and 1.62 (95% CI, 1.16-2.28) in the overall, mild, and severe psoriasis groups, respectively. No significant association was seen with cancer of the breast, colon, prostate, or leukemia.

Conclusions and Relevance  The association between psoriasis and cancer, albeit small, was present in our cohort of patients with psoriasis. This association was primarily driven by NMSC, lymphoma, and lung cancer.

×